Medtronic DBS Therapy demonstrates efficacy in Parkinson’s trial

Medtronic has published new data which illustrates the potential benefits of its deep brain stimulation (DBS) technology among Parkinson’s disease sufferers.

The firm’s Medtronic DBS Therapy was evaluated over a two-year period among 299 patients, with different groups receiving DBS via the subthalamic nucleus or the globus pallidus interna.

It was found that the treatment exhibited similar levels of efficacy among both groups, providing significant improvements in motor function and quality of life.

Tom Tefft, president of the neuromodulation business and senior vice-president at Medtronic, said the results demonstrated the long-term benefits and positive impact its treatment can deliver.

He added: “These results are representative of Medtronic’s commitment to provide innovative, long-term solutions for patients with chronic disease.”

Last month, Medtronic announced positive findings from a clinical trial of its Arctic Front Cardiac CryoAblation catheter system, which was shown to deliver superior performance against paroxysmal atrial fibrillation than drug therapy.